Abbott Laboratories
$97.50Change from previous close: +0.84%Absolute change: +$0.81
At a glance
- Revenue growth
- +5.67%
- 2025 vs 2024
- Net income growth
- −51.32%
- 2025 vs 2024
- Net margin
- 14.7%
- 2024: 31.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 9,566 | 8,558 | 7,261 | 9,581 | 10,533 | 7,901 | 6,136 | 6,300 | 5,570 | 3,203 |
| Depreciation and amortization | 3,116 | 3,218 | 3,243 | 3,267 | 3,538 | 3,327 | 3,014 | 3,278 | 3,019 | 1,351 |
| Capital expenditure | -2,171 | -2,207 | -2,202 | -1,777 | -1,885 | -2,177 | -1,638 | -1,394 | -1,135 | -1,121 |
| Investing cash flow | -2,422 | -2,338 | -3,133 | -1,740 | -2,008 | -2,215 | -1,815 | -1,356 | -9,618 | -248 |
| Financing cash flow | -6,309 | -5,404 | -7,091 | -7,636 | -5,494 | -2,779 | -4,289 | -10,391 | -5,281 | 11,147 |
| Dividends paid | -4,116 | -3,836 | -3,556 | -3,309 | -3,202 | -2,560 | -2,270 | -1,974 | -1,849 | -1,539 |
| Share repurchases | -893 | -1,295 | -1,227 | -3,795 | -2,299 | -403 | -718 | -238 | -117 | -522 |
| Debt issued | 5.0 | 223 | 23.0 | 54.0 | 4.0 | 1,283 | 1,842 | 4,009 | 6,742 | 14,934 |
| Debt repaid | -1,619 | -760 | -2,498 | -753 | -252 | -1,333 | -3,441 | -12,459 | -9,684 | -1,779 |
| Effect of exchange rates | 71.0 | -96.0 | -23.0 | -122 | -70.0 | 71.0 | -16.0 | -116 | 116 | -483 |
| Net change in cash | 906 | 720 | -2,986 | 83.0 | 2,961 | 2,978 | 16.0 | -5,563 | -9,213 | 13,619 |
| Free cash flow | 7,395 | 6,351 | 5,059 | 7,804 | 8,648 | — | — | — | — | — |
| Levered free cash flow | 6,289 | 5,610 | 4,990 | 7,340 | 7,675 | 5,269 | 3,843 | 4,842 | 3,893 | 1,755 |